+

WO1998037180A2 - Protease hybride du vhc et polynucleotide codant cette derniere - Google Patents

Protease hybride du vhc et polynucleotide codant cette derniere Download PDF

Info

Publication number
WO1998037180A2
WO1998037180A2 PCT/US1998/003367 US9803367W WO9837180A2 WO 1998037180 A2 WO1998037180 A2 WO 1998037180A2 US 9803367 W US9803367 W US 9803367W WO 9837180 A2 WO9837180 A2 WO 9837180A2
Authority
WO
WIPO (PCT)
Prior art keywords
seq
protease
polynucleotide
fusion protein
virus
Prior art date
Application number
PCT/US1998/003367
Other languages
English (en)
Other versions
WO1998037180A3 (fr
Inventor
Chih-Ming Chen
Akhteruzzaman Molla
Rakesh L. Tripathi
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of WO1998037180A2 publication Critical patent/WO1998037180A2/fr
Publication of WO1998037180A3 publication Critical patent/WO1998037180A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/503—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses
    • C12N9/506—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses derived from RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Definitions

  • the present invention relates in general to recombinant proteins and recombinant polynucleotides encoding such proteins. More particularly, the present invention concerns a biologically active protease of HCV, to polypeptide analogs thereof and to polynucleotides encoding the same.
  • HCV Hepatitis C virus
  • HCV HCV
  • the HCV genome has a single open reading frame that encodes a precursor polyprotein of about 3,000 amino acid residues.
  • polyprotein is composed of at least 10 viral proteins which appear in the following order: NH2-Core-El-E2-p7-NS2-NS3-NS4A- NS4B-NS5A-NS5B-COOH.
  • the Core nucleocapsid
  • El envelope type 1 and type 2 proteins
  • the "NS” proteins are believed to be non-structural and involved in viral RNA replication.
  • NS2/3 is a metalloprotease, and is encoded in the regions from the C-terminal portion of NS2 to the N-terminal one-third of
  • the NS2/3 protease cleaves the NS2/NS3 junction of native HCV polyprotein in cis.
  • the second protease designated "NS3" is a serine-type protease encoded in the N-terminal one-third of NS3.
  • the NS3 protease cleaves at all known NS junctions located downstream from the NS3 region, namely, at the NS3/4A, NS4A/4B, NS4B/5A and NS5A/5B junction sites. (Sitoh, S., et al., J. Virol., 69(7): 4255-4260 ( 1995).
  • NS3 protease processing at the NS3/4A junction appears to take place exclusively as an intramolecular or cotranslational reaction (in cis).
  • cleavage at the other sites can also be mediated intermolecularly or posttranslationally (i.e. in trans) (Steinkuhler, C, et al., op. cit.).
  • cleavage by the NS3 protease at the NS4B/NS5A junction requires an additional cofactor protein encoded by NS4A (see Failla, C. et al., J. Virol. , 68(6): 3753-
  • NS4A may act by stabilizing the active conformation of the NS3 protease domain and recruiting NS3 to the membranes, where presumable proteolytic processing takes place (Hijikata, M. et al., Proc. Nad. Acad. Sci. USA 90: 10773-10777 (1993)).
  • NS4A and NS3 interact to effect cleavage at the NS4B/5A junction.
  • the NS3 protease is likely to be an essential enzyme for viral growth, it has become a target for the development of anti-HCV drugs.
  • assays have been developed to screen for drugs which inhibit NS3 protease activity. In such assays, it is generally necessary to provide at least a cleavable substrate, an NS3 protease capable of cleaving the substrate and a compound of interest
  • the cleavable portion of the substrate is an NS4B/5A junction, it is also necessary to provide a sufficient quantity of NS4A cofactor protein to bring about efficient cleavage.
  • a second complication that arises is in having to make and/or purify the two proteins separately and then empirically determine the proper proportions of each protein to add to the assay in order to achieve efficient cleavage.
  • This second problem is particularly difficult to overcome, since biologically active NS3 protease is autocleavable at the NS3/4A junction, and therefore self-cleaves itself from NS4A during the purification process.
  • biologically active NS3 protease is autocleavable at the NS3/4A junction, and therefore self-cleaves itself from NS4A during the purification process.
  • the present invention provides an isolated or purified polynucleotide, comprising a nucleotide sequence (A) having a nucleotide sequence (B) or fragments thereof which encode hepatitis C virus NS3 protease and a nucleotide sequence (C) or fragments thereof which encode NS4A cofactor protein, wherein the nucleotide sequence (A) produces, upon expression, a non-autocleavable fusion protein of hepatitis C virus NS3 protease and hepatitis C virus NS4 cofactor protein which is biologically active.
  • the nucleotide sequence (B) is located upstream from nucleotide sequence (C).
  • the nucleotide (A) encodes a biologically active fusion protein which is capable of cleaving at least SEQ LD NO: 15.
  • the nucleotide sequence (B) encodes a biologically active domain of NS3 protease.
  • the nucleotide sequence (B) comprises from about nucleotide position 1 to about nucleotide position 543 of SEQ ID NO:l.
  • the nucleotide sequence (C) encodes a biologically active domain of NS4A cofactor protein which more preferably, comprises from about nucleotide position 1957 to about nucleotide position 1995 of SEQ ID NO: 1.
  • the nucleotide sequence (A) has the sequence of SEQ ID NO:3.
  • a polynucleotide of the present invention is contained in an expression vector.
  • the expression vector preferably further comprises an enhancer-promoter operatively linked to the polynucleotide.
  • a preferred expression vector is pGEX.
  • the pGEX vector comprises the polynucleotide of SEQ ED NO:3.
  • the present invention still further provides for a host cell transformed with an expression vector of this invention.
  • the host cell may be a eukaryotic or prokaryotic cell.
  • the host cell is E. coli.
  • the present invention also provides a biologically active fusion polypeptide comprising hepatitis C virus NS3 protease and hepatitis C virus NS4A cofactor protein which is non- autocleavable.
  • the fusion protein is capable of cleaving at least SEQ ID NO: 16 and preferably, also cleaves a substrate comprising SEQ ID NO:6, SEQ LD NO:7, SEQ ID NO:8 or SEQ ID NO:9.
  • the fusion protein has SEQ LD NO:4.
  • the present invention provides a method for identifying an inhibitor compound of hepatitis C virus NS3 protease comprising the steps of (a) providing a reaction mixture having (i) a substrate wherein the substrate is capable of being cleaved by a hepatitis C virus NS3 protease acting alone or in combination with a hepatitis C virus NS4A cofactor protein, ( ⁇ ) a non-autocleavable fusion protein of hepatitis C virus NS3 protease and hepatitis C virus NS4A cofactor protein which is biologically active and (iii) a compound of interest; (b) incubating said reaction mixture; and (c) deterrriining the extent of cleavage of said substrate in said reaction mixture.
  • the fusion protein has SEQ LD
  • FIG. 1 shows a partial polynucleotide sequence of an HCV genome, strain H (SEQ ID NO: 1
  • FIG. 2 shows a polynucleotide sequence (SEQ ID NO:3) which encodes an NS3/4A fusion protein of the present invention.
  • This particular sequence represents the sense sequence of SEQ LD NO: l from about nucleotide position 1 to about nucleotide position 612 and from about nucleotide position 1894 to about nucleotide position 2055.
  • FIG. 3 shows the polypeptide sequence (SEQ ID NO:4) encoded from SEQ ID NO:2.
  • FIG. 4 shows a graph of the results of a kinetics assay performed as described in Example 3.
  • the closed circles, plus sign symbols, "x" symbols and open circles represent fluorescence points obtained from assays performed in the presence of pT-3 fusion protein, glutathione S transferase (GST), GST coupled to cytomegalovirus (CMV) protease, and no enzyme, respectively.
  • GST glutathione S transferase
  • CMV cytomegalovirus
  • FIG. 5 depicts the HPLC analysis of cleavage products after incubation of a purified GST-NS3/4A fusion protein with a cleavable substrate (i.e. SEQ ID NO: 16) .
  • the assay was performed under conditions described in Example 3 (Total Qeavage Assay). Aliquots from the total cleavage assay were withdrawn at the time points indicated to the left of the HPLC tracings. Time points indicated below the tracings show the peak retention times.
  • the dotted lines represent 470 nm absorption and the solid lines represent the fluorescence tracing with excitation at 355nm and emission at 490 nm.
  • FIG. 6 schematically shows the T3 and NS3 series of fusion constructs of NS3/4A [FIG 6(a)] and NS3 [FIG 6(b)] fused downstream of maltose binding protein and protease cleavage sites in pMAL vectors.
  • the present invention provides polynucleotide sequences which encode a fusion protein of hepatitis C virus (hereinafter HCV) NS3 protease and hepatitis C virus NS4A cofactor protein.
  • HCV hepatitis C virus
  • Such sequences may include: the incorporation of codons "preferred" for expression by desired non-mammalian hosts, the provision of sites for cleavage by restriction endonuclease enzymes; and the provision of additional initial, terminal or intermediate DNA sequences which facilitate construction of readily expressed vectors.
  • the present invention provides a recombinant fusion protein of hepatitis C virus which is biologically active. Furthermore, the invention also includes expression vectors for high level expression and easy purification and host cells transformed with such vectors.
  • NS3 protease refers to a serine-type protease encoded by HCV which is capable, either alone or in combination with NS4A cofactor protein (described below), of cleaving a substrate having an HCV non- structural (NS) cleavage junction (defined below).
  • NS3 protease is intended to encompass protease analogs (defined below) provided such analogs also possess the ability to cleave an HCV NS cleavage junction as described below.
  • NS4A cofactor or "NS4A cofactor protein” as used herein refers to a protein encoded by HCV which acts in combination with NS3 protease, to effect cleavage of a substrate having an HCV non-structural (NS) cleavage junction as described below.
  • NS4A cofactor is believed to effect cleavage by stabilizing the NS3 protease and/or recruiting NS3 protease to the membrane, the actual mechanism by which NS4A cofactor acts "in combination" with NS3 protease is unknown.
  • NS4A cofactor is also intended to include protein analogs of NS4A cofactor provided those analogs possess the ability to act in combination with NS3 protease to effect cleavage of a cleavage junction.
  • polypeptide refers to a molecular chain of amino acids and does not refer to a specific length of the product. Thus, peptides, oligopeptides and proteins are included within the definition of polypeptide. Hepatitis C virus NS3 protease and NS4A cofactor protein are representative examples of polypeptides. This term is also intended to refer to post-expression modifications of the polypeptide. for example, glycosylations. acetylations, phosphorylations and the like.
  • fusion protein refers to a polypeptide comprising an amino acid sequence drawn from two or more individual proteins.
  • a fusion protein is formed by the expression of a polynucleotide in which at least two coding sequences have been joined together such that their reading frames are in frame.
  • Examples of fusion proteins of the present invention include a polypeptide comprising NS3 protease joined to NS4A cofactor protein or an NS3/4A fusion protein further joined to a biological tag. Such fusion proteins may or may not be capable of being cleaved into the separate proteins from which they are derived.
  • cleavage junction or “non- structural cleavage junction” as used herein refers to a polypeptide comprising a continguous sequence of amino acids having the formula X6-X5- X4-X3-X2-X1-X1' (SEQ ID NO:5) wherein X6 represents D or E, Xi represents T or C, Xr represents A or S and X2, X3, X4, and X5 represent any amino acid.
  • a cleavage junction is further defined as one which NS3 protease alone or in combination with NS4A cofactor protein can cleave. As determined by Steinkuhler et al., (J. Biol. Chem., 271(11): 6367-
  • the amino acid sequence "D/E-X5-X4-X3-X2-C-A/S” represents a consensus sequence for all NS3 trans cleavage sites (i.e. sites which are cleaved by NS3 protease alone or in combination with NS4A via an intermolecular reaction).
  • each single letter i.e. D, E, C, A and S
  • the slash symbol "/" designates the word "or”
  • X2-X5 represent any amino acids.
  • the consensus sequence for in cis or (intramolecular) cleavage differs slightly from the other in having a T (threonine) residue present instead of C at the X1 position.
  • C and T are PI residues
  • a and S are PI ' residues
  • X2-X5 are residues P2, P3, P4 and P5 and D or E is the P6 residue.
  • Xi represents a PI residue
  • Xr a PI' residue
  • cleavable substrate refers to a polypeptide comprising at least the cleavable junction of SEQ ID NO:5. Examples of cleavable substrates include a native HCV polyprotein and fragments thereof.
  • NS5A/5B EDVVCCS (SEQ ID NO:9).
  • Even more preferred cleavable substrates comprise sequences selected from the group consisting of DLEWTSTVWL (SEQ LD NO: 10), DEMEECSQHLP (SEQ ID NO: 11), ECTTPCSGSWL (SEQ LD NO: 12), and EDWCCSMSYT (SEQ LD NO: 13).
  • Other preferred cleavable substrates include E-A-G-D-D- I-V-P-C-S-M-S-Y-T-W-T-G-A (SEQ ID NO: 14, see Shimizu et al., Virology 70(1): 127-132
  • Cleavable substrates may be generated in any manner well known to those of ordinary skill in the art, such as by synthetic means or by proteolytic digestion of a native HCV polyprotein. Cleavable substrates need not be of any specific length but preferably provide detectable cleavage products upon cleavage of the substrate. For example, cleavage products may be assayed by western blot or if the cleavage substrate has been radiolabled, by autoradiography techniques.
  • one or more ends may be labeled with an enzyme so as to permit visualization of the protein products. It is presently preferred to employ small peptide p- nitrophenyl esters or methylcoumarins, as cleavage may then be followed by spectrophotometric or fluorescent assays. For example, following the method described by E.D. Matayoshi et al, (Science, 247: 231-235 (1990)) one may attach a fluorescent label to one end of the substrate and a quenching molecule to the other end; cleavage is then determined by measuring the resulting increase in fluorescence.
  • cleavable substrate is Ac-G-E(EDANS)-(ethylene glycol Unker)-E-D-V-V-A-C-S-M-S-Y-(ethylene glycol linker)- K(Dabycl)-G-NH2 (SEQ LD NO: 16).
  • isolated means that the material is removed from its original environment
  • a naturally-occurring polynucleotide or polypeptide present in a living animal is not isolated, but the same polynucleotide or DNA or polypeptide, which is separated from some or all of the coexisting materials in the natural system, is isolated.
  • Such polynucleotide could be part of a vector and/or such polynucleotide or polypeptide could be part of a composition, and still be isolated in that the vector or composition is not part of its natural environment
  • polynucleotide as used herein means a polymeric form of nucleotides of any length, either ribonucleotides or deoxyribonucleotides. This term refers only to the primary structure of the molecule. Thus, the term includes double- and single-stranded DNA, as well as double- and single-stranded RNA. It also includes modifications, either by methylation and/or by capping, and unmodified forms of the polynucleotide.
  • Polynucleotide refers to a polynucleotide of interest or fragment thereof which is essentially free, i.e., contains less than about 50%, preferably less than about 70%, and more preferably, less than about 90% of the protein with which the polynucleotide is naturally associated.
  • Techniques for purifying polynucleotides of interest include, for example, disruption of the cell containing the polynucleotide with a chaotropic agent and separation of the polynucleotide(s) and proteins by ion-exchange chromatography, affinity chromatography and sedimentation according to density.
  • purified polypeptide means a polypeptide of interest or fragment thereof which is essentially free, that is, contains less than about 50%, preferably less than about 70%, and more preferably, less than about 90% of cellular components with which the polypeptide of interest is naturally associated. Methods for purifying are well known to those of ordinary skill in the art.
  • ORF open reading frame
  • recombinant protein or “recombinant polypeptide” as used herein refers to at least a polypeptide of genomic, semisynthetic or synthetic origin which by virtue of its origin or manipulation is not associated with all or a portion of the polypeptide with which it is associated in nature or in the form of a library and/or is linked to a polypeptide other than that to which it is linked in nature.
  • a recombinant polypeptide may be translated from a designated sequence of HCV or HCV genome. However, it also may be generated in other ways, such as by chemical synthesis or via expression in a recombinant expression system, or by isolation from a mutated HCV.
  • recombinant host cells refer to cells which can be, or have been, used as recipients for recombinant vector or other transfer DNA, and include the original progeny of the original cell which has been transfected.
  • replicon means any genetic element, such as a plasmid, a chromosome, a virus, that behaves as an autonomous unit of polynucleotide replication within a cell. Otherwise stated, a replicon is a genetic element which is capable of replication under its own control.
  • control sequence refers to polynucleotide sequences which are necessary to effect the expression of coding sequences to which they are ligated. The nature of such control sequences differs depending upon the host organism. In prokaryotes, such control sequences generally include promoters, ribosomal binding sites and terminators; in eukaryotes, such control sequences generally include promoters, terminators and in some instances, enhancers. Thus the term “control sequence” is intended to include at a minimum all components whose presence is necessary for expression, and also may include additional components whose presence is advantageous, for example, leader sequences.
  • operatively linked refers to a situation in which the components described are are in a relationship permitting them to function in their intended manner.
  • a control sequence "operatively linked" to a coding sequence is ligated in such a manner that expression of the coding sequence is achieved under conditions compatible with the control sequences.
  • T e term "coding sequence" as used herein refers to a polynucleotide sequence which is transcribed into mRNA and/or translated into a polypeptide when placed under the control of appropriate regulatory sequences. The boundaries of the coding sequence are determined by a translation start codon at the 5 '-terminus and a translation stop codon at the 3 '-terminus.
  • a coding sequence can include, but is not limited to, mRNA, cDNA and recombinant polypeptide sequences.
  • transformation refers to the insertion of an exogenous polynucleotide into a host cell, irrespective of the method used for the insertion. For example, direct uptake, transduction, or f-mating are included.
  • the exogenous polynucleotide may be maintained as a non-integrated vector such as for example, a plasmid, or alternativelym may be integrated into the host genome.
  • the present invention provides an isolated or purified polynucleotide comprising a nucleotide sequence (A) which encodes a fusion protein of NS3 protease and
  • NS4A cofactor protein from hepatitis C virus (HCV).
  • HCV hepatitis C virus
  • NS3/4A fusion protein the fusion protein expressed from such a nucleotide will be referred to as "NS3/4A fusion protein”.
  • FIG. 1 shows a partial polynucleotide sequence of an HCV genome (strain H), specifically, the polynucleotide sequence encoding native NS3 protease and NS4A cofactor protein and is intended to represent both the sense strand (as shown) and its complement
  • the polypeptide encoded therefrom (SEQ LD NO:2) is shown below with standard one letter codes for the amino acids appearing beneath their respective nucleic acid codons.
  • the nucleotide sequence which encodes NS3 protease is located from about nucleotide position 1 to about nucleotide position 1893.
  • nucleotide sequence known to encode a biologically active NS3 protease is from about nucleotide position 1 to about nucleotide position 546.
  • SEQ ID NO:l Also shown in SEQ ID NO:l is a nucleotide sequence of NS4A cofactor protein, which is located from about nucleotide position 1894 to about nucleotide position 2055.
  • the smallest portion of nucleotide sequence known to encode a biologically active NS4A cofactor protein is from about nucleotide position 1954 to about nucleotide position 1995.
  • SEQ LD NO: 1 the polynucleotide contains a continuous open reading frame.
  • a polynucleotide sequence of the present invention comprises a nucleotide sequence (A) derived from SEQ LD NO: 1 having a nucleotide sequence (B) which encodes an NS3 protease and a nucleotide sequence (C) which encodes an NS4A cofactor protein in a continuous translational open reading frame.
  • the polynucleotide comprises a nucleotide sequence having the sense sequence of SEQ LD NO: 1 from about nucleotide position 1 to about nucleotide position 612 and about nucleotide position 1894 to about nucleotide position 2055.
  • FIG. 2 SEQ ID NO:3
  • the sequence which encodes the NS3 protease is located upstream (in front of) the sequence which encodes the NS4A cofactor protein (see again
  • polynucleotide is a DNA molecule.
  • polynucleotide is an RNA molecule.
  • a polynucleotide sequence of the present invention is further defined as one which encodes a non-autocleavable fusion protein of NS3 protease and NS4A cofactor protein.
  • Such a polynucleotide is one which lacks the nucleotide sequence that encodes SEQ ID NO:5; accordingly, the fusion protein encoded from the polynucleotide will not itself contain a cleavable junction.
  • SEQ ID NO: 3 lacks the nucleotide sequence encoding the terminal portion of native NS3 protease (i.e.
  • the NS3 portion of the polypeptide encoded from SEQ ID NO:3 is unable to cleave itself from the fusion protein (shown in FIG.
  • a non-autocleavable fusion protein is to be generated from an autocleavable sequence (such as an HCV genome or portion thereof), one or more of the SEQ ID NO:5 nucleotides contained within that genomic sequence may be eliminated either by deletion, mutation or addition of sequence (so as to disrupt SEQ ID NO:5).
  • an autocleavable sequence such as an HCV genome or portion thereof
  • SEQ ID NO:5 nucleotides contained within that genomic sequence may be eliminated either by deletion, mutation or addition of sequence (so as to disrupt SEQ ID NO:5).
  • the only requirements are that the resulting nucleotide sequence encode a non-autocleavable junction and retain an open reading frame between the coding regions of NS3 and NS4A so that the polypeptide encoded therefrom will be biologically active.
  • a polypeptide of the present invention For the purpose of measuring biological activity only, a polypeptide of the present invention must be shown to cleave at least a cleavable substrate SEQ ID NO: 16 when tested as described in Example 3 below. It is to be understood however, that such a polypeptide may also cleave other cleavable substrates, both natural and synthetic.
  • a biologically active protease encoded from a polynucleotide of the present invention may also possess the ability to cleave a native HCV genome or fragments thereof or other cleavable substrates as described herein.
  • the present invention also contemplates shorter and longer polynucleotide sequences (other than that shown in SEQ LD NO:3) which encode an NS3/NS4A fusion protein provided that the fusion protein possesses the characteristics of being non-autocleavable and biologically active.
  • the present invention also contemplates polynucleotide sequences which encode the smallest proteolytic domain of an NS3 protease (i.e. from about nucleotide position 1 to about nucleotide position 543 of SEQ ID NO:l) or the smallest proteolytic domain of an NS4A cofactor protein (i.e.
  • the polynucleotides contemplated by the present invention include those which contain at least active domains of NS3 protease and NS4A cofactor protein.
  • the sequences when constructing such polynucleotide sequences, the sequences must retain the characteristics of having a single open reading frame and of encoding a non-autocleavable fusion protein.
  • Standard molecular biology techniques are used for generating such polynucleotides and are well known to those of ordinary skill in the art (see for example, Sambrook et al., Molecular Cloning: A Laboratory Manual, Second Edition, (Cold Spring Harbor, N.Y., 1989).
  • the present invention also contemplates analogous DNA sequences which hybridize under stringent hybridization conditions to the DNA sequences set forth above. Stringent hybridization conditions are well known in the art and define a degree of sequence identity greater than about 80% and more preferably, greater than about 90%.
  • the modifier "analogous” also refers to those nucleotide sequences that encode polypeptides having only conservative differences and which retain the conventional characteristics and activities of an NS3/NS4A fusion protein; eg.
  • the present invention also contemplates naturally occurring allelic variations and mutations of the DNA sequences set forth above so long as those variations and mutations code, on expression, for an NS3/4A fusion protein of this invention as set forth hereinafter.
  • DNA and RNA molecules that can code for the same polypeptide as those of a particular sequence.
  • the present invention contemplates those other DNA and RNA molecules which, on expression, encode for the polypeptide of NS3/4A fusion protein or fragments thereof. Having identified the amino acid residue sequence encoded by an NS3/4A polynucleotide, and with knowledge of all triplet codons for each particular amino acid residue, it is possible to describe all such encoding RNA and DNA sequences. DNA and RNA molecules other than those specifically disclosed herein and, which molecules are characterized simply by a change in a codon for a particular amino acid are within the scope of this invention.
  • a polynucleotide of the present invention can also be an RNA molecule.
  • a RNA molecule contemplated by the present invention is complementary to or hybridizes under stringent conditions to any of the DNA sequences set forth above.
  • Exemplary and preferred RNA molecules are mRNA molecules that encode an NS3/NS4A fusion protein of this invention.
  • the present invention provides a fusion protein of NS3 protease and NS4A cofactor of HCV.
  • An NS3/NS4A fusion protein of the present invention is a polypeptide of from about 194 amino acid residues which has the ability to cleave at least SEQ ID NO: 16 when tested as described in Example 3 below.
  • Such an NS3/4A fusion protein may also have the ability to cleave other cleavable substrates including but not limited to a native HCV genome and fragments thereof.
  • an NS3/4A fusion protein of the present invention is non-autocleavable, meaning that the fusion protein itself SEQ LD NO: 16.
  • the amino acid sequence of an exemplary NS3/4A fusion protein is set forth in FIG. 3 (SEQ LD NO:4).
  • the present invention also contemplates amino acid residue sequences that are substantially duplicative of the sequences set forth herein such that those sequences demonstrate like biological activity to disclosed sequences.
  • Such contemplated sequences include those sequences characterized by a minimal change in amino acid residue sequence or type (e.g., conservatively substituted sequences) which insubstantial change does not alter the fundamental nature and biological activity of an NS3/4A fusion protein.
  • modifications and changes can be made in the structure of a polypeptide without substantially altering the biological function of that peptide.
  • certain amino acids can be substituted for other amino acids in a given polypeptide without any appreciable loss of function.
  • substitutions of like amino acid residues can be made on the basis of relative similarity of side-chain substituents, for example, their size, charge, hydrophobicity, hydrophilicity, and the like.
  • hydrophilicity values have been assigned to amino acid residues: Arg (+3.0); Lys (+3.0); Asp (+3.0); Glu (+3.0); Ser (+0.3); Asn (+0.2); Gin (+0.2); Gly (0); Pro (-0.5); Thr (-0.4); Ala (-0.5); His (-0.5); Cys (-1.0); Met (-1.3); Val (-1.5); Leu (-1.8); lie (-1.8); Tyr (-2.3); Phe (-2.5); and Trp (-3.4). It is understood that an amino acid residue can be substituted for another having a similar hydrophilicity value (e.g., within a value of plus or minus 2.0) and still obtain a biologically equivalent polypeptide.
  • a similar hydrophilicity value e.g., within a value of plus or minus 2.0
  • the present invention provides a process for making a polynucleotide NS3/4A fusion protein.
  • a suitable host cell is transformed with a polynucleotide of the present invention.
  • the transformed cell is maintained for a period of time sufficient for expression of the NS3/4A fusion protein; the fusion protein is then recovered.
  • the polynucleotide which encodes NS3 protease and/or NS4A cofactor can be obtained in varous ways.
  • the HCV nucleic acid can be isolated and cloned from viral particles obtained from individuals infected with the virus.
  • the gene encoding NS3 protease can also be obtained using the plasmid disclosed in Grakoui, A. et al., J. Virology, 67(3):
  • the polynucleotide of the invention can be chemically synthesized by means well known in the art. (See for example, Matteucci, et al., J. Am. Chem. Soc, 103: 3185 (1981) and B.R. Glick and Pasternak, Molecular Biotechnology, ASM Press, Washington, D.C. pages 55-63 (1994)). Furthermore, the HCV genome has been disclosed in PCT International Application WO 89/04669 and is available from the American Type Culture collection (ATCC), 12301 Parklawn Drive, Rockville, MD under Accession No. 40394. a.
  • prokaryotic and eukaryotic host cells may be used for expression of desired coding sequences when appropriate control sequences which are compatible with the designated host are used.
  • E. coli is most frequently used.
  • Expression control sequences for prokaryotics include promoters, optionally containing operator portions, and ribosome binding sites.
  • Transfer vectors compatible with prokaryotic hosts are commonly derived from the plasmid pBR322 which contains operons conferring ampicillin and tetracycline resistance, and the various pUC vectors, which also contain sequences conferring antibiotic resistance markers. There markers may be used to obtain successful transformants by selection.
  • prokaryotic control sequences include the beta-lactamase (penicillinase), lactose promoter system (Chang et al., Nature 198:1056 (1977)), the tryptophan promoter system (reported by Goeddel et al., Nucleic Acid Res. 8: 4057 (1980)) and the lambda-derived PI promoter and N gene ribosome binding site (Shimatake et al., Nature 292: 128 (1081) and the hybrid Jac promoter (De Boer et al., Proc. Natl. Acad. Sci. USA 292: 128 (1983)) derived from sequences of the Sp_ and kc UV5 promoters.
  • the foregoing systems are particularly compatible with E. coli; however, other prokaryotic hosts such as strains of Bacillus or Pseudomonas may be used if desired, with corresponding control sequences.
  • Eukaryotic hosts include yeast, mammalian and insect cells in culture systems. Saccharomyces cerevisiae and Saccharomyces carlsbergensis are the most commonly used yeast hosts, and are convenient fungal hosts.
  • Yeast compatible vectors carry markers which permit selection of successful transformants by conferring protrophy to auxotrophic mutants or resistance to heavy metals on wild-type strains.
  • Yeast compatible vectors may employ the 2 micron origin of replication (as described by Broach et al., Meth. Enz. 101: 307 (1983), the combination of CEN3 and ARS 1 or other means for assuring replication, such as sequences which will result in incorporation of an appropriate fragment into the host cell genome.
  • Control sequences for yeast vectors are known in the art and include promoters for the synthesis of glycolytic enzymes, including the promoter for 3 phosphophycerate kinase. See, for example, Hess et al.J. Adv. Enzyme Reg. 7: 149 (1968), Holland et al., Biochemistry 17:4900 (1978) and Hitzeman, J. Biol. Chem. 255: 2073 ( 1980). Terminators also may be included, such as those derived from the enolase gene as reported by Holland, J. Biol. Chem. 256: 1385 (1981).
  • particularly useful control systems are those which comprise the glyceraldehyde-3 phosphate dehydrogenase (GAPDH) promoter or alcohol dehydrogenase (ADH) regulatable promoter, terminators also derived from GAPDH, and if secretion is desired, leader sequences from yeast alpha factor.
  • GPDH glyceraldehyde-3 phosphate dehydrogenase
  • ADH alcohol dehydrogenase
  • terminators also derived from GAPDH
  • leader sequences from yeast alpha factor if secretion is desired, leader sequences from yeast alpha factor.
  • the transcriptional regulatory region and the transcriptional initiation region which are operably linked may be such that they are not naturally associated in the wild-type organism.
  • Mammalian cell lines available as hosts for expression are known in the art and may include many immortalized cell lines which are available from the American Type Culture Collection. These include HeLa cells, Chinese hamster overy (CHO) cells, baby hamster kidney (BHK) cells, and the like. Suitable promoters for mammalian cells also are known in the art and include viral promoters such as that from Simian Virus 40 (SV40), Rous sarcoma virus (RSV), adenovirus (ADV), bovine papilloma virus (BPV), and cytomegalovirus (CMV).
  • Simian Virus 40 SV40
  • Rous sarcoma virus RSV
  • ADV adenovirus
  • BBV bovine papilloma virus
  • CMV cytomegalovirus
  • Mammalian cells also may require terminator sequences and poly A addition sequences; enhancer sequences which increase expression also may be included as well as sequences which cause amplification of a gene. Such sequences are well known in the art.
  • Vectors suitable for replication in mammalian cells may include viral replicons, or sequences which insure integration of the appropriate sequences in a host genome.
  • An example of a mammalian expression system for HCV is described in U.S. Patent Application Serial No. 07/830,024, filed January 31, 1992.
  • Insect cell lines are also available as hosts and are well known to those of ordinary skill in the an. Cloning vehicles such as baculovirus may be used in such cell lines.
  • the present invention also comtemplates the use of expression vectors which facilitate purification of a desired polypeptide.
  • a polynucleotide encoding the desired fusion protein may be cloned into an expression vector which, when expressed, produces the fusion protein linked to a chemical or biological tag.
  • a tag may be any chemical or biological compound or fragment thereof capable of binding to a specific substrate or receptor.
  • tags serve to facilitate purf ⁇ cation of a tagged fusion product via specific binding of the tag portion to its receptor or substrate.
  • the tag is linked to the polypeptide in a manner that permits it to be cleaved from the polypeptide after purification, without affecting the activity of the polypeptide.
  • a polynucleotide of the present invention may be cloned into a pGEX vector (Pharmacia Biotech. Inc., Piscataway, New Jersey) and placed in a suitable host; on expression, a fusion protein of NS3/NS4A and glutathione S-transferase (GST) is produced.
  • the fusion protein is then purified by affinity chromatography using glutathione sepharose 4B (which binds to the GST portion of the fusion product).
  • the NS3/4A fusion protein is then cleaved from the GST tag using a site-specific protease whose recognition sequence is located upstream from the NS3/4A fusion protein.
  • affinity tags may also be used and linked to either end of the desired protein (i.e. either amino or carboxyl terminus).
  • tags such as 6-His (available from Novagen, Madison, WI), hexa-Arg (see G. Stempfer et al., Nature Biotechnology 14: 481-484 (1996)), FLAG (available from VWR, Chicago, IL), maltose binding protein (MBP, see Kellerman and Ference, Methods in Enzymology 90: 459-463, 1992) and thioredoxin (Trx, see La Value, et al., Bio/Technology 11: 187- 193, 1993) may also be used and are well known to routineers.
  • b. Transformations such as 6-His (available from Novagen, Madison, WI), hexa-Arg (see G. Stempfer et al., Nature Biotechnology 14: 481-484 (1996)), FLAG (available from VWR, Chicago, IL), maltose binding protein (MBP, see Kellerman and Ference, Method
  • Means for transforming host cells in a manner such that those cells produce recombinant polypeptides are well known in the art. Such methods include direct uptake of a polynucleotide, packaging a polynucleotide in a virus, and transducing a host cell with a virus. The transformation procedures selected depends upon the host to be transformed. For example, bacterial transformation by direct uptake generally employs treatment with calcium or rubidium chloride. Cohen, Proc. Natl. Acad. Sci. USA 69: 2110 (1972). Yeast transformation by direct uptake may be conducted using the calcium phosphate precipitation method of Graham et al., Virology 52: 526 (1978) or modification thereof, c. Vector Construction Vector construction employs methods known in the art.
  • site-specific DNA cleavage is performed by treating with suitable restriction enzymes under conditions which generally are specified by the manufacturer of these commercially available enzymes.
  • suitable restriction enzymes usually, about 1 microgram ( ⁇ g) of plasmid or DNA sequence is cleaved by 1 unit of enzyme in about 20 ⁇ l of buffer solution by incubation at 37 °C for 1 to 2 hours. After incubation with the restriction enzyme, protein is removed by phenol/chloroform extraction and the DNA recovered by precipitation with ethanol.
  • the cleaved fragments may be separated using polyacrylamide or agarose gel electrophoresis methods, according to methods known by the routine practitioner.
  • Ligations are performed using standard buffer and temperature conditions using T4 DNA ligase and ATP. Sticky end ligations require less ATP and less ligase than blunt end ligations.
  • the vector fragment often is treated with bacterial alkaline phosphatase (BAP) or calf intestinal alkaline phosphatase to remove the 5 '-phosphate and thus prevent religation of the vector.
  • BAP bacterial alkaline phosphatase
  • restriction enzyme digestion of unwanted fragments can be used to prevent ligation.
  • Ligation mixtures are transformed into suitable cloning hosts such as E coli and successful transformants selected by methods including antibiotic resistance, and then screened for the correct construct.
  • NS3/4A fusion protein of the present invention has numerous uses.
  • such a polypeptide can be used in large or small scale in vitro assays for identifying compounds that inhibit the activity of the fusion protein.
  • a fusion protein of the present invention may be incubated with a cleavable substrate and a compound of interest.
  • compounds which prevent the formation of cleavage products are potential inhibitors of protease activity.
  • An NS3/4A fusion protein can also be used to design compounds that interact with and inhibit the fusion protein.
  • the fusion protein may be used for structural studies by NMR or X-ray diffraction, thereby facilitating drug design.
  • Plasmid pBRTM/HCV 1-3011 containing the gene encoding the full length HCV-H polyprotein was purchased from Dr. Charles Rice of Washington University School of Medicine. Restriction enzymes were purchased from commercial suppliers such as Boehringer Mannheim (Indianapolis, IN), GEBCO BRL (Gaithersburg, MD) and New England Biolab (Beverly, MA) unless otherwise indicated. Chemicals were purchased from Sigma Chemical Co. (St Louis, MO).
  • Plasmid pBRTM/HCV was digested with Kas I and the 2.4 kb fragment (i.e. nucleotides (nt) 7606-10034) was isolated by gel elution. The fragment was treated with Klenow and ligated into vector pHLL-S l (Invitrogen,San Diego, CA) which had been cut with Sma I and dephosphorylated with calf intestinal alkaline phosphatase (CIAP) in order to generate plasmid pRLT-2. Plasmid pRLT-2 contained the entire open reading frames (ORFs) of both NS3 and NS4A and part of the ORF of NS4B.
  • ORFs open reading frames
  • Plasmid pRLT-3 was then generated by digesting pRLT-2 with Eel XI and Bam HI, gel eluting the approximately 10 kilobase pair (kb) linearized band, treating the fragment with Klenow and religating the fragment to generate a plasmid which encoded only NS3 (7606-9476 nt).
  • pRLT-3 was subsequently digested with Xho I to generate a 1 kb fragment which was gel eluted, purified and ligated into Xho I digested and dephosphorylated pGEX-4T-2 (Pharmacia Biotech, Inc., Piscataway, New Jersey) to generate plasmid pT- 1.
  • Plasmid pT-1 was then digested with Sph I and Not I and the 5.584 kb fragment containing the NS3 portion was gel-purified and ligated to the 209 base pair Sphl/Not I fragment of NS4A to generate plasmid pT-3.
  • Plasmid pT-3 was transformed into E. coli strain JM109 (Promega, Madison, WI) for expression studies. Expression of plasmid pT-3 was shown (by SDS-PAGE gel electrophoresis) to produce a fusion protein of NH2-GST- NS3-NS4A-COOH of approximately 54.8 kD.
  • TP/liter 20 g tryptone, 15 g yeast extract 8 g NaCl, 2 g Na2HPO4, and 1 g KH2PO4), ampicillin (Amp, 100 ug/ml) and 0.2% dextrose was inoculated with a single colony of pT-3/JM109 and shaken at 250 rpm at 37°C for 16 hours.
  • This culture was used to inoculate (at a 1:50 dilution) 1 liter of TP broth (including the named antibiotics and dextrose) in a 2.8 Liter Fernback flask.
  • the culture was shaken at 37°C for 2 hours, after which 1 mL of 100 mM EPTG was added and the culture shaken for an additional 2 hours.
  • the culture was then aliquoted (250 ml aliquots) into Coming centrifuge bottles (Cat No. 25350-250) and the cells harvested by centrifuging at 2,000 rpm in a Sorvall GSA rotor at 4°C. The supernatant was discarded and the wet pellet weighed.
  • the pellets were frozen in a dry ice/ethanol bath and stored at -80°C until further use.
  • a 250 ml culture pellet was thawed and resuspended in 10 ml IX STE (10 mM Tris, pH 8.0, 150 mM NaCl, 1 mM EDTA).
  • the cells were lysed with a French press cell two times at 20 kpsi and the lysate placed into plastic 15 ml oakridge tubes.
  • Triton X-100 10% solution in lx PBS (137 mM NaCl, 2.7 mM KC1, 4.3 mM Na HPO 4 , 1.4 mM KH PO 4 , pH 7.4) was added to the lysate to a final concentration of 1.0% and the solution was mixed gently at room temperature for 30 minutes.
  • DTT (either solid or a 1 M stock) was added to a final concentration of 20 mM and the solution again mixed gently at room temperature for 5 minutes. The solution was placed on ice for 1 hour and then centrifuged at 14,000 rpm in a Sorvall
  • Elution buffer (lOmL, having 50 mM Tricine, pH 8.0, 10 mM reduced glutathione, 5 mM DTT, and 1% Triton X-100) was then applied to the column, collected in fractions and assayed for protease activity in the manner described in Example 3 below. Fractions having enzyme activity were stored in elution buffer at -80°C until future use. Total protein content was later determined by detergent compatible Bradford assay (BioRad, Hercules, CA).
  • Fluorogenic peptide substrate having the sequence Ac-G- E(EDANS)-(ethylene glycol linker)-E-D-V-V-A-C-S-M-S-Y-(ethylene glycol linker)- K(Dabycl)-G-NH2 (hereinafter termed "FPS- 1") was synthesized and purified according to the procedure of E. D. Matayoshi et. al., Science 247: 954, 1990.
  • FPS-1 is a cleavage substrate having a modified NS5A/5B cleavage junction, the modification being the substitution of amino acid A for the P2 amino acid C in SEQ LD NO:13.
  • FPS-1 the PI amino acid is C and the PI ' amino acid is S. Accordingly, proper cleavage of FPS- 1 results in the following two products: Ac-G-E(EDANS)-(ethylene glycol linker)-E-D-V-V-A-C (SEQ LD NO: 19) and S-M-
  • Kinetics assays (for determining fusion protein activity) were performed as 200 ⁇ L reactions containing 50 mM Tricine, pH 8.0; 30 % glycerol, 0.2% Triton X-100, 6 ⁇ M synthetic peptide substrate (pre-incubated as a 50 ⁇ M solution in 2 mM DTT for at least 30 minutes prior to use) with purified GST-NS3/4A fusion protein.
  • GST protein, a fusion protein of GST-CMV protease or no protein were used in place of GST-NS3/4A fusion protein under otherwise identical reaction conditions.
  • Assay mixtures were incubated at room temperature and the progress of the reaction monitored for up to 1 hour in a Titertek Fluoroskan II instrument (ICN Biomedicals, Huntsville, AL) with an excitation filter set at 335 nm and emission filter at 485 nm. Data was collected online with a Macintosh computer using DELTA SOFT II, version 4.0 (BioMetallics, Inc., Princeton, NJ). Nonlinear curve fitting was performed using KaleidaGraph (Synergy Software, Reading, PA).
  • Fusion proteins were generated and experiments performed to demonstrate that NS3/4A fusion proteins of the present invention have full cw-cleavage activity. Such proteins are envisioned for use to screen compounds which inhibit the protease activity and/or to study the protease substrate requirement by mutagenesis methods.
  • HCV NS3 protein [corresponding to amino acid positions 1-181 of SEQ LD NO:4 and designated as "NS3 series" in FIG. 6(b)] as well as NS3/NS4A fusion protein (corresponding to SEQ ID NO:4 and designated as "T3 series" in FIG.
  • HCV NS3 serine protease cleavage sites were also inserted between the maltose binding protein (MBP) and the serine protease domain.
  • NS3/4A site DLEWT-STWV (amino acids 1- lO of SEQ LD NO: 10); NS4A/4B site: DEMEEC-SQHL (amino acids 1-10 of SEQ ED NO:ll); NS4B/5A site: ECTTPC-SGSW (amino acids 1-10 of SEQ LD NO: 12); and NS5A/5B site: EDVVCC-SMSY (SEQ ID NO: 15).
  • the scissile bond is indicated by a dash (-).
  • An active site mutation also was generated in the 5A/5B cut site construct (called pMAL-5AB-D81N) within the NS3 protein at amino acid position 81. At that position, the Asp was mutated to Asn (and is referred to in FIG. 6(b) as D81N). To complete the constructs, a six histidine tag was linked to the carboxy terminus of each of these fusion proteins.
  • the constructs were transformed into E. coli JM109 bacteria. Synthesis of the fusion proteins was induced using IPTG under standard conditions. Gene products were analyzed by SDS-PAGE, Western blot analysis and MBP affinity purification. MBP fusion proteins were purified using amylose resin (New England BioLabs) whereas the his-tagged polypeptides were purified by Talon metal affinity resin (Clontech, Palo Alto, CA). Western analysis was performed with anti-His antibody (Invitrogen, Carlsbad, CA) and visualized with an ECL Western blotting analysis system (Amersham, Arlington Hights, LL). All procedures described in this example were performed using standard molecular biology and biochemistry techniques or according to manufacturer's instructions. b. Results: When the whole cell lysate of JM109 containing the construct pMAL-23-
  • T3 was analyzed by SDA-PAGE, an overexpressed MBP fusion protein of 63.5 KD in size was easily visualized by Coomassie blue staining. Protein purification carried out on this lysate by amylose affinity chromatography also retrieved this 63.5 KD polypeptide.
  • the fusion protein demonstrated full NS3 serine protease activity in the peptide cleavage assay described above (in Example 3).

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Cette invention concerne des protéines hybrides biologiquement actives de la protéase NS3 du virus de l'hépatite C et la protéine du cofacteur NS4A, qui sont non autoclivables, ainsi que des polynucléotides codant ces dernières; des vecteurs d'expression comprenant les polynucléotides et des cellules hôtes transformées avec ces mêmes polynucléotides; et un procédé permettant d'identifier des composés d'inhibiteur de la protéase NS3 du virus de l'hépatite C à l'aide des protéines hybrides de cette invention.
PCT/US1998/003367 1997-02-22 1998-02-20 Protease hybride du vhc et polynucleotide codant cette derniere WO1998037180A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80426697A 1997-02-22 1997-02-22
US08/804,266 1997-02-22

Publications (2)

Publication Number Publication Date
WO1998037180A2 true WO1998037180A2 (fr) 1998-08-27
WO1998037180A3 WO1998037180A3 (fr) 1998-11-19

Family

ID=25188568

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/003367 WO1998037180A2 (fr) 1997-02-22 1998-02-20 Protease hybride du vhc et polynucleotide codant cette derniere

Country Status (1)

Country Link
WO (1) WO1998037180A2 (fr)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1102992A1 (fr) * 1998-08-05 2001-05-30 Agouron Pharmaceuticals, Inc. Systeme a gene rapporteur pour l'evaluation precaracterisee d'inhibiteurs de la protease du virus de l'hepatite c
WO2001002601A3 (fr) * 1999-07-07 2001-07-26 Du Pont Pharm Co Systemes de dosage cellulaire destines a l'examen de l'activite de la protease ns3 hcv
WO2002014362A3 (fr) * 2000-08-17 2003-11-13 Tripep Ab Gene de fusion non structurel ns3/4a du virus de l'hepatite c
US7012066B2 (en) 2000-07-21 2006-03-14 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
US7022830B2 (en) 2000-08-17 2006-04-04 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
US7169760B2 (en) 2000-07-21 2007-01-30 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
US7244715B2 (en) 2000-08-17 2007-07-17 Tripep Ab Vaccines containing ribavirin and methods of use thereof
US7244721B2 (en) 2000-07-21 2007-07-17 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
WO2018121602A1 (fr) * 2016-12-27 2018-07-05 天津天锐生物科技有限公司 Système de changement de la fonction d'une protéine commandé par un médicament à petites molécules
JP2022518488A (ja) * 2019-01-25 2022-03-15 センティ バイオサイエンシズ インコーポレイテッド タンパク質機能を制御するための融合構築物

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6680059B2 (en) 2000-08-29 2004-01-20 Tripep Ab Vaccines containing ribavirin and methods of use thereof
WO2009022236A2 (fr) 2007-08-16 2009-02-19 Tripep Ab Plate-forme immunogène

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1272179B (it) * 1994-02-23 1997-06-16 Angeletti P Ist Richerche Bio Metodologia per riprodurre in vitro l'attivita' proteolitica della proteasi ns3 del virus hcv.
US5843752A (en) * 1995-05-12 1998-12-01 Schering Corporation Soluble active hepatitis C virus protease

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6790612B2 (en) 1998-08-05 2004-09-14 Agouron Pharmaceuticals, Inc. Reporter gene system for use in cell-based assessment of inhibitors of the hepatitis C virus protease
EP1102992A4 (fr) * 1998-08-05 2003-07-30 Agouron Pharma Systeme a gene rapporteur pour l'evaluation precaracterisee d'inhibiteurs de la protease du virus de l'hepatite c
EP1102992A1 (fr) * 1998-08-05 2001-05-30 Agouron Pharmaceuticals, Inc. Systeme a gene rapporteur pour l'evaluation precaracterisee d'inhibiteurs de la protease du virus de l'hepatite c
WO2001002601A3 (fr) * 1999-07-07 2001-07-26 Du Pont Pharm Co Systemes de dosage cellulaire destines a l'examen de l'activite de la protease ns3 hcv
US7169760B2 (en) 2000-07-21 2007-01-30 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
US7012066B2 (en) 2000-07-21 2006-03-14 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
US7244721B2 (en) 2000-07-21 2007-07-17 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
US7595299B2 (en) 2000-07-21 2009-09-29 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
USRE43298E1 (en) 2000-07-21 2012-04-03 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
US6960569B2 (en) 2000-08-17 2005-11-01 Tripep Ab Hepatitis C virus non-structural NS3/4A fusion gene
US7022830B2 (en) 2000-08-17 2006-04-04 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
WO2002014362A3 (fr) * 2000-08-17 2003-11-13 Tripep Ab Gene de fusion non structurel ns3/4a du virus de l'hepatite c
US7244715B2 (en) 2000-08-17 2007-07-17 Tripep Ab Vaccines containing ribavirin and methods of use thereof
EP1947185A1 (fr) * 2000-08-17 2008-07-23 Tripep Ab Acide nucléique codant pour HCV NS3/4A
EP2332574A1 (fr) * 2000-08-17 2011-06-15 Tripep Ab Séquences de HCV NS3/4A
WO2018121602A1 (fr) * 2016-12-27 2018-07-05 天津天锐生物科技有限公司 Système de changement de la fonction d'une protéine commandé par un médicament à petites molécules
JP2022518488A (ja) * 2019-01-25 2022-03-15 センティ バイオサイエンシズ インコーポレイテッド タンパク質機能を制御するための融合構築物

Also Published As

Publication number Publication date
WO1998037180A3 (fr) 1998-11-19

Similar Documents

Publication Publication Date Title
US7033805B2 (en) HCV NS3 protein fragments having helicase activity and improved solubility
AU691259B2 (en) Method for reproducing in vitro the proteolytic activity of the NS3 protease of hepatitis C virus (HCV)
CA2079105C (fr) Protease du virus de l'hepatite c
Steinkühler et al. Activity of purified hepatitis C virus protease NS3 on peptide substrates
JP3091231B2 (ja) 可溶性で活性なｃ型肝炎ウイルスプロテアーゼ
AU2003280239B2 (en) Inhibitor-resistant HCV NS3 protease
WO1999028482A2 (fr) Complexes recombinants monocatenaires de la protease ns3 et du peptide co-facteur ns4a du virus de l'hepatite c (vhc)
AU716379B2 (en) Methodology to produce, purify and assay polypeptides with the proteolytic activity of the HCV NS3 protease
WO1998037180A2 (fr) Protease hybride du vhc et polynucleotide codant cette derniere
JP3878132B2 (ja) 精製活性型ｈｃｖｎｓ２／３プロテアーゼ
Moria et al. Enzymatic characterization of purified NS3 serine proteinase of hepatitis C virus expressed in Escherichia coli
Kakiuchi et al. Cleavage activity of hepatitis C virus serine proteinase
JPH07184648A (ja) Ｈｃｖプロテイナーゼ活性物質、その製造法並びに同プロテイナーゼおよび同プロテイナーゼ阻害剤のアッセイ法
Kim et al. Chiron Corporation, 4560 Horton St, Emeryville, CA 94608
JPH06315377A (ja) 分子間反応により部位特異的切断を行うｈｃｖ由来プロテイナーゼ活性物質およびその精製法

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP MX

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1998536916

Format of ref document f/p: F

122 Ep: pct application non-entry in european phase
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载